오가노이드 시장

Organoids Market- Scope of Report

TMR's report on the global Organoids Marketstudies the past as well as the current growth trends and opportunities to gain valuable insights of the indicators of the Market during the forecast period from 2025 to 2035. The report provides revenue of the global Organoids Marketfor the period 2025 to 2035, considering 2025 as the base year and 2035 as the forecast year. The report also provides the compound annual growth rate (CAGR %) of the global Organoids Marketfrom 2025 to 2035.

The report has been prepared after an extensive research. Primary research involved bulk of the research efforts, wherein analysts carried out interviews with key opinion leaders, industry leaders, and opinion makers. Secondary research involved referring to key players' product literature, annual reports, press releases, and relevant documents to understand the Organoids Market .

Secondary research also included Internet sources, statistical data from government agencies, websites, and trade associations. Analysts employed a combination of top-down and bottom-up approaches to study various attributes of the global Organoids Market .

The report includes an elaborate executive summary, along with a snapshot of the growth behavior of various segments included in the scope of the study. Moreover, the report throws light on the changing competitive dynamics in the global Organoids Market . These serve as valuable tools for existing Market players as well as for entities interested in participating in the global Organoids Market .

The report delves into the competitive landscape of the global Organoids Market . Key players operating in the global Organoids Markethave been identified and each one of these has been profiled in terms of various attributes. Company overview, financial standings, recent developments, and SWOT are the attributes of players in the global Organoids Marketprofiled in this report.

Key Questions Answered in Global Organoids MarketReport:

• What are the opportunities in the global Organoids Market ?
• What are the major drivers, restraints, opportunities, and threats in the Market ?
• Which regional Market is set to expand at the fastest CAGR during the forecast period?
• Which segment is expected to generate the highest revenue globally in 2035?
• Which segment is projected to expand at the highest CAGR during the forecast period?
• What are the Market positions of different companies operating in the global Market ?

Organoids Market- Research Objectives and Research Approach

The comprehensive report on the global Organoids Marketbegins with an overview, followed by the scope and objectives of the study. The report provides detailed explanation of the objectives behind this study and key vendors and distributors operating in the Market and regulatory scenario for approval of products.

For reading comprehensibility, the report has been compiled in a chapter-wise layout, with each section divided into smaller ones. The report comprises an exhaustive collection of graphs and tables that are appropriately interspersed. Pictorial representation of actual and projected values of key segments is visually appealing to readers. This also allows comparison of the Market shares of key segments in the past and at the end of the forecast period.

The report analyzes the global Organoids Marketin terms of product, end-user, and region. Key segments under each criterion have been studied at length, and the Market share for each of these at the end of 2035 has been provided. Such valuable insights enable Market stakeholders in making informed business decisions for investment in the global Organoids Market .

Table of Contents

1. Preface

• 1.1. Market Definition and Scope
• 1.2. Market Segmentation
• 1.3. Key Research Objectives
• 1.4. Research Highlights

2. Assumptions and Research Methodology

3. Executive Summary : Global Organoids Market

4. Market Overview

• 4.1. Introduction
  • 4.1.1. Segment Definition
• 4.2. Overview
• 4.3. Market Dynamics
  • 4.3.1. Drivers
  • 4.3.2. Restraints
  • 4.3.3. Opportunities
• 4.4. Global Organoids Market Analysis and Forecasts, 2020 to 2035
  • 4.4.1. Market Revenue Projections (US$ Bn)

5. Key Insights

• 5.1. Healthcare Expenditure across Key Regions / Countries
• 5.2. Recent Advancements in Organoid Technology
• 5.3. Pricing Trends for Organoids
• 5.4. Regulatory Scenario across Key Regions / Countries
• 5.5. PORTER's Five Forces Analysis
• 5.6. PESTEL Analysis
• 5.7. Value Chain Analysis
• 5.8. Key Purchase Metrics for End-users
• 5.9. Go-to-Market Strategy for New Market Entrants
• 5.10. Key Industry Events (Partnerships, Collaborations, Product approvals, mergers & acquisitions)
• 5.11. Benchmarking of Key Products Offered by the Leading Competitors

6. Global Organoids Market Analysis and Forecasts, By Type of Organoid

• 6.1. Introduction & Definition
• 6.2. Key Findings / Developments
• 6.3. Market Value Forecast By Type of Organoid, 2020 to 2035
  • 6.3.1. Stomach Organoids
  • 6.3.2. Intestinal Organoids
  • 6.3.3. Liver Organoids
  • 6.3.4. Lung Organoids
  • 6.3.5. Brain Organoids
  • 6.3.6. Kidney Organoids
  • 6.3.7. Colorectal Organoids
  • 6.3.8. Breast Organoids
  • 6.3.9. Prostate Organoids
  • 6.3.10. Skin Organoids
  • 6.3.11. Retina Organoids
  • 6.3.12. Others
• 6.4. Market Attractiveness By Type of Organoid

7. Global Organoids Market Analysis and Forecasts, By Source

• 7.1. Introduction & Definition
• 7.2. Key Findings / Developments
• 7.3. Market Value Forecast By Source, 2020 to 2035
  • 7.3.1. Pluripotent Stem Cells (PSCs)
    • 7.3.1.1. Embryonic Stem Cells (ESCs)
    • 7.3.1.2. Induced Pluripotent Stem Cells (iPSCs)
  • 7.3.2. Adult Stem Cells (ASCs)
  • 7.3.3. Patient-derived Organoids
• 7.4. Market Attractiveness By Source

8. Global Organoids Market Analysis and Forecasts, By Application

• 8.1. Introduction & Definition
• 8.2. Key Findings / Developments
• 8.3. Market Value Forecast By Application, 2020 to 2035
  • 8.3.1. Developmental Biology
  • 8.3.2. Regenerative Medicine
  • 8.3.3. Disease Modelling
  • 8.3.4. Drug Toxicity and Efficacy Testing
  • 8.3.5. Biomarker Discovery
  • 8.3.6. Others
• 8.4. Market Attractiveness By Application

9. Global Organoids Market Analysis and Forecasts, By Usability

• 9.1. Introduction & Definition
• 9.2. Key Findings / Developments
• 9.3. Market Value Forecast By Usability, 2020 to 2035
  • 9.3.1. Ready-to-Use Organoids
  • 9.3.2. Customizable Organoids
• 9.4. Market Attractiveness By Usability

10. Global Organoids Market Analysis and Forecasts, By Storage Conditions

• 10.1. Introduction & Definition
• 10.2. Key Findings / Developments
• 10.3. Market Value Forecast By Storage Conditions, 2020 to 2035
  • 10.3.1. Shelf-stable Organoids
  • 10.3.2. Cryopreserved Organoids
• 10.4. Market Attractiveness By Storage Conditions

11. Global Organoids Market Analysis and Forecasts, By End-user

• 11.1. Introduction & Definition
• 11.2. Key Findings / Developments
• 11.3. Market Value Forecast By End-user, 2020 to 2035
  • 11.3.1. Pharmaceutical and Biotechnology Companies
  • 11.3.2. Contract Research Organizations (CROs)
  • 11.3.3. Academic and Research Institutions
• 11.4. Market Attractiveness By End-user

12. Global Organoids Market Analysis and Forecasts, By Region

• 12.1. Key Findings
• 12.2. Market Value Forecast By Region
  • 12.2.1. North America
  • 12.2.2. Europe
  • 12.2.3. Asia Pacific
  • 12.2.4. Latin America
  • 12.2.5. Middle East & Africa
• 12.3. Market Attractiveness By Region

13. North America Organoids Market Analysis and Forecast

• 13.1. Introduction
  • 13.1.1. Key Findings
• 13.2. Market Value Forecast By Type of Organoid, 2020 to 2035
  • 13.2.1. Stomach Organoids
  • 13.2.2. Intestinal Organoids
  • 13.2.3. Liver Organoids
  • 13.2.4. Lung Organoids
  • 13.2.5. Brain Organoids
  • 13.2.6. Kidney Organoids
  • 13.2.7. Colorectal Organoids
  • 13.2.8. Breast Organoids
  • 13.2.9. Prostate Organoids
  • 13.2.10. Skin Organoids
  • 13.2.11. Retina Organoids
  • 13.2.12. Others
• 13.3. Market Value Forecast By Source, 2020 to 2035
  • 13.3.1. Pluripotent Stem Cells (PSCs)
    • 13.3.1.1. Embryonic Stem Cells (ESCs)
    • 13.3.1.2. Induced Pluripotent Stem Cells (iPSCs)
  • 13.3.2. Adult Stem Cells (ASCs)
  • 13.3.3. Patient-derived Organoids
• 13.4. Market Value Forecast By Application, 2020 to 2035
  • 13.4.1. Developmental Biology
  • 13.4.2. Regenerative Medicine
  • 13.4.3. Disease Modelling
  • 13.4.4. Drug Toxicity and Efficacy Testing
  • 13.4.5. Biomarker Discovery
  • 13.4.6. Others
• 13.5. Market Value Forecast By Usability, 2020 to 2035
  • 13.5.1. Ready-to-Use Organoids
  • 13.5.2. Customizable Organoids
• 13.6. Market Value Forecast By Storage Conditions, 2020 to 2035
  • 13.6.1. Shelf-stable Organoids
  • 13.6.2. Cryopreserved Organoids
• 13.7. Market Value Forecast By End-user, 2020 to 2035
  • 13.7.1. Pharmaceutical and Biotechnology Companies
  • 13.7.2. Contract Research Organizations (CROs)
  • 13.7.3. Academic and Research Institutions
• 13.8. Market Value Forecast By Country , 2020 to 2035
  • 13.8.1. U.S.
  • 13.8.2. Canada
• 13.9. Market Attractiveness Analysis
  • 13.9.1. By Type of Organoid
  • 13.9.2. By Source
  • 13.9.3. By Application
  • 13.9.4. By Usability
  • 13.9.5. By Storage Conditions
  • 13.9.6. By End-user
  • 13.9.7. By Country

14. Europe Organoids Market Analysis and Forecast

• 14.1. Introduction
  • 14.1.1. Key Findings
• 14.2. Market Value Forecast By Type of Organoid, 2020 to 2035
  • 14.2.1. Stomach Organoids
  • 14.2.2. Intestinal Organoids
  • 14.2.3. Liver Organoids
  • 14.2.4. Lung Organoids
  • 14.2.5. Brain Organoids
  • 14.2.6. Kidney Organoids
  • 14.2.7. Colorectal Organoids
  • 14.2.8. Breast Organoids
  • 14.2.9. Prostate Organoids
  • 14.2.10. Skin Organoids
  • 14.2.11. Retina Organoids
  • 14.2.12. Others
• 14.3. Market Value Forecast By Source, 2020 to 2035
  • 14.3.1. Pluripotent Stem Cells (PSCs)
    • 14.3.1.1. Embryonic Stem Cells (ESCs)
    • 14.3.1.2. Induced Pluripotent Stem Cells (iPSCs)
  • 14.3.2. Adult Stem Cells (ASCs)
  • 14.3.3. Patient-derived Organoids
• 14.4. Market Value Forecast By Application, 2020 to 2035
  • 14.4.1. Developmental Biology
  • 14.4.2. Regenerative Medicine
  • 14.4.3. Disease Modelling
  • 14.4.4. Drug Toxicity and Efficacy Testing
  • 14.4.5. Biomarker Discovery
  • 14.4.6. Others
• 14.5. Market Value Forecast By Usability, 2020 to 2035
  • 14.5.1. Ready-to-Use Organoids
  • 14.5.2. Customizable Organoids
• 14.6. Market Value Forecast By Storage Conditions, 2020 to 2035
  • 14.6.1. Shelf-stable Organoids
  • 14.6.2. Cryopreserved Organoids
• 14.7. Market Value Forecast By End-user, 2020 to 2035
  • 14.7.1. Pharmaceutical and Biotechnology Companies
  • 14.7.2. Contract Research Organizations (CROs)
  • 14.7.3. Academic and Research Institutions
• 14.8. Market Value Forecast By Country / Sub-region , 2020 to 2035
  • 14.8.1. Germany
  • 14.8.2. UK
  • 14.8.3. France
  • 14.8.4. Italy
  • 14.8.5. Spain
  • 14.8.6. Switzerland
  • 14.8.7. The Netherlands
  • 14.8.8. Rest of Europe
• 14.9. Market Attractiveness Analysis
  • 14.9.1. By Type of Organoid
  • 14.9.2. By Source
  • 14.9.3. By Application
  • 14.9.4. By Usability
  • 14.9.5. By Storage Conditions
  • 14.9.6. By End-user
  • 14.9.7. By Country / Sub-region

15. Asia Pacific Organoids Market Analysis and Forecast

• 15.1. Introduction
  • 15.1.1. Key Findings
• 15.2. Market Value Forecast By Type of Organoid, 2020 to 2035
  • 15.2.1. Stomach Organoids
  • 15.2.2. Intestinal Organoids
  • 15.2.3. Liver Organoids
  • 15.2.4. Lung Organoids
  • 15.2.5. Brain Organoids
  • 15.2.6. Kidney Organoids
  • 15.2.7. Colorectal Organoids
  • 15.2.8. Breast Organoids
  • 15.2.9. Prostate Organoids
  • 15.2.10. Skin Organoids
  • 15.2.11. Retina Organoids
  • 15.2.12. Others
• 15.3. Market Value Forecast By Source, 2020 to 2035
  • 15.3.1. Pluripotent Stem Cells (PSCs)
    • 15.3.1.1. Embryonic Stem Cells (ESCs)
    • 15.3.1.2. Induced Pluripotent Stem Cells (iPSCs)
  • 15.3.2. Adult Stem Cells (ASCs)
  • 15.3.3. Patient-derived Organoids
• 15.4. Market Value Forecast By Application, 2020 to 2035
  • 15.4.1. Developmental Biology
  • 15.4.2. Regenerative Medicine
  • 15.4.3. Disease Modelling
  • 15.4.4. Drug Toxicity and Efficacy Testing
  • 15.4.5. Biomarker Discovery
  • 15.4.6. Others
• 15.5. Market Value Forecast By Usability, 2020 to 2035
  • 15.5.1. Ready-to-Use Organoids
  • 15.5.2. Customizable Organoids
• 15.6. Market Value Forecast By Storage Conditions, 2020 to 2035
  • 15.6.1. Shelf-stable Organoids
  • 15.6.2. Cryopreserved Organoids
• 15.7. Market Value Forecast By End-user, 2020 to 2035
  • 15.7.1. Pharmaceutical and Biotechnology Companies
  • 15.7.2. Contract Research Organizations (CROs)
  • 15.7.3. Academic and Research Institutions
• 15.8. Market Value Forecast By Country / Sub-region , 2020 to 2035
  • 15.8.1. China
  • 15.8.2. India
  • 15.8.3. Japan
  • 15.8.4. South Korea
  • 15.8.5. Australia & New Zealand
  • 15.8.6. Rest of Asia Pacific
• 15.9. Market Attractiveness Analysis
  • 15.9.1. By Type of Organoid
  • 15.9.2. By Source
  • 15.9.3. By Application
  • 15.9.4. By Usability
  • 15.9.5. By Storage Conditions
  • 15.9.6. By End-user
  • 15.9.7. By Country / Sub-region

16. Latin America Organoids Market Analysis and Forecast

• 16.1. Introduction
  • 16.1.1. Key Findings
• 16.2. Market Value Forecast By Type of Organoid, 2020 to 2035
  • 16.2.1. Stomach Organoids
  • 16.2.2. Intestinal Organoids
  • 16.2.3. Liver Organoids
  • 16.2.4. Lung Organoids
  • 16.2.5. Brain Organoids
  • 16.2.6. Kidney Organoids
  • 16.2.7. Colorectal Organoids
  • 16.2.8. Breast Organoids
  • 16.2.9. Prostate Organoids
  • 16.2.10. Skin Organoids
  • 16.2.11. Retina Organoids
  • 16.2.12. Others
• 16.3. Market Value Forecast By Source, 2020 to 2035
  • 16.3.1. Pluripotent Stem Cells (PSCs)
    • 16.3.1.1. Embryonic Stem Cells (ESCs)
    • 16.3.1.2. Induced Pluripotent Stem Cells (iPSCs)
  • 16.3.2. Adult Stem Cells (ASCs)
  • 16.3.3. Patient-derived Organoids
• 16.4. Market Value Forecast By Application, 2020 to 2035
  • 16.4.1. Developmental Biology
  • 16.4.2. Regenerative Medicine
  • 16.4.3. Disease Modelling
  • 16.4.4. Drug Toxicity and Efficacy Testing
  • 16.4.5. Biomarker Discovery
  • 16.4.6. Others
• 16.5. Market Value Forecast By Usability, 2020 to 2035
  • 16.5.1. Ready-to-Use Organoids
  • 16.5.2. Customizable Organoids
• 16.6. Market Value Forecast By Storage Conditions, 2020 to 2035
  • 16.6.1. Shelf-stable Organoids
  • 16.6.2. Cryopreserved Organoids
• 16.7. Market Value Forecast By End-user, 2020 to 2035
  • 16.7.1. Pharmaceutical and Biotechnology Companies
  • 16.7.2. Contract Research Organizations (CROs)
  • 16.7.3. Academic and Research Institutions
• 16.8. Market Value Forecast By Country / Sub-region , 2020 to 2035
  • 16.8.1. Brazil
  • 16.8.2. Mexico
  • 16.8.3. Argentina
  • 16.8.4. Rest of Latin America
• 16.9. Market Attractiveness Analysis
  • 16.9.1. By Type of Organoid
  • 16.9.2. By Source
  • 16.9.3. By Application
  • 16.9.4. By Usability
  • 16.9.5. By Storage Conditions
  • 16.9.6. By End-user
  • 16.9.7. By Country / Sub-region

17. Middle East & Africa Organoids Market Analysis and Forecast

• 17.1. Introduction
  • 17.1.1. Key Findings
• 17.2. Market Value Forecast By Type of Organoid, 2020 to 2035
  • 17.2.1. Stomach Organoids
  • 17.2.2. Intestinal Organoids
  • 17.2.3. Liver Organoids
  • 17.2.4. Lung Organoids
  • 17.2.5. Brain Organoids
  • 17.2.6. Kidney Organoids
  • 17.2.7. Colorectal Organoids
  • 17.2.8. Breast Organoids
  • 17.2.9. Prostate Organoids
  • 17.2.10. Skin Organoids
  • 17.2.11. Retina Organoids
  • 17.2.12. Others
• 17.3. Market Value Forecast By Source, 2020 to 2035
  • 17.3.1. Pluripotent Stem Cells (PSCs)
    • 17.3.1.1. Embryonic Stem Cells (ESCs)
    • 17.3.1.2. Induced Pluripotent Stem Cells (iPSCs)
  • 17.3.2. Adult Stem Cells (ASCs)
  • 17.3.3. Patient-derived Organoids
• 17.4. Market Value Forecast By Application, 2020 to 2035
  • 17.4.1. Developmental Biology
  • 17.4.2. Regenerative Medicine
  • 17.4.3. Disease Modelling
  • 17.4.4. Drug Toxicity and Efficacy Testing
  • 17.4.5. Biomarker Discovery
  • 17.4.6. Others
• 17.5. Market Value Forecast By Usability, 2020 to 2035
  • 17.5.1. Ready-to-Use Organoids
  • 17.5.2. Customizable Organoids
• 17.6. Market Value Forecast By Storage Conditions, 2020 to 2035
  • 17.6.1. Shelf-stable Organoids
  • 17.6.2. Cryopreserved Organoids
• 17.7. Market Value Forecast By End-user, 2020 to 2035
  • 17.7.1. Pharmaceutical and Biotechnology Companies
  • 17.7.2. Contract Research Organizations (CROs)
  • 17.7.3. Academic and Research Institutions
• 17.8. Market Value Forecast By Country / Sub-region , 2020 to 2035
  • 17.8.1. GCC Countries
  • 17.8.2. South Africa
  • 17.8.3. Rest of Middle East & Africa
• 17.9. Market Attractiveness Analysis
  • 17.9.1. By Type of Organoid
  • 17.9.2. By Source
  • 17.9.3. By Application
  • 17.9.4. By Usability
  • 17.9.5. By Storage Conditions
  • 17.9.6. By End-user
  • 17.9.7. By Country / Sub-region

18. Competition Landscape

• 18.1. Market Player - Competition Matrix (By Tier and Size of companies)
• 18.2. Market Share Analysis By Company (2024)
• 18.3. Company Profiles
  • 18.3.1. Danaher Corporation
    • 18.3.1.1. Company Overview
    • 18.3.1.2. Financial Overview
    • 18.3.1.3. Product Portfolio
    • 18.3.1.4. Business Strategies
    • 18.3.1.5. Recent Developments
  • 18.3.2. Merck KGaA
    • 18.3.2.1. Company Overview
    • 18.3.2.2. Financial Overview
    • 18.3.2.3. Product Portfolio
    • 18.3.2.4. Business Strategies
    • 18.3.2.5. Recent Developments
  • 18.3.3. 3Dnamics Inc.
    • 18.3.3.1. Company Overview
    • 18.3.3.2. Financial Overview
    • 18.3.3.3. Product Portfolio
    • 18.3.3.4. Business Strategies
    • 18.3.3.5. Recent Developments
  • 18.3.4. ATCC
    • 18.3.4.1. Company Overview
    • 18.3.4.2. Financial Overview
    • 18.3.4.3. Product Portfolio
    • 18.3.4.4. Business Strategies
    • 18.3.4.5. Recent Developments
  • 18.3.5. STEMCELL Technologies
    • 18.3.5.1. Company Overview
    • 18.3.5.2. Financial Overview
    • 18.3.5.3. Product Portfolio
    • 18.3.5.4. Business Strategies
    • 18.3.5.5. Recent Developments
  • 18.3.6. CelVivo ApS
    • 18.3.6.1. Company Overview
    • 18.3.6.2. Financial Overview
    • 18.3.6.3. Product Portfolio
    • 18.3.6.4. Business Strategies
    • 18.3.6.5. Recent Developments
  • 18.3.7. Emulate, Inc.
    • 18.3.7.1. Company Overview
    • 18.3.7.2. Financial Overview
    • 18.3.7.3. Product Portfolio
    • 18.3.7.4. Business Strategies
    • 18.3.7.5. Recent Developments
  • 18.3.8. Newcells Biotech
    • 18.3.8.1. Company Overview
    • 18.3.8.2. Financial Overview
    • 18.3.8.3. Product Portfolio
    • 18.3.8.4. Business Strategies
    • 18.3.8.5. Recent Developments
  • 18.3.9. ACROBiosystems
    • 18.3.9.1. Company Overview
    • 18.3.9.2. Financial Overview
    • 18.3.9.3. Product Portfolio
    • 18.3.9.4. Business Strategies
    • 18.3.9.5. Recent Developments
  • 18.3.10. Corning Incorporated
    • 18.3.10.1. Company Overview
    • 18.3.10.2. Financial Overview
    • 18.3.10.3. Product Portfolio
    • 18.3.10.4. Business Strategies
    • 18.3.10.5. Recent Developments
  • 18.3.11. Pandorum Technologies Pvt. Ltd.
    • 18.3.11.1. Company Overview
    • 18.3.11.2. Financial Overview
    • 18.3.11.3. Product Portfolio
    • 18.3.11.4. Business Strategies
    • 18.3.11.5. Recent Developments
  • 18.3.12. MIMETAS B.V.
    • 18.3.12.1. Company Overview
    • 18.3.12.2. Financial Overview
    • 18.3.12.3. Product Portfolio
    • 18.3.12.4. Business Strategies
    • 18.3.12.5. Recent Developments
  • 18.3.13. Organovo Holdings Inc.
    • 18.3.13.1. Company Overview
    • 18.3.13.2. Financial Overview
    • 18.3.13.3. Product Portfolio
    • 18.3.13.4. Business Strategies
    • 18.3.13.5. Recent Developments
  • 18.3.14. Crown Bioscience
    • 18.3.14.1. Company Overview
    • 18.3.14.2. Financial Overview
    • 18.3.14.3. Product Portfolio
    • 18.3.14.4. Business Strategies
    • 18.3.14.5. Recent Developments
  • 18.3.15. OrganoTherapeutics SARL
    • 18.3.15.1. Company Overview
    • 18.3.15.2. Financial Overview
    • 18.3.15.3. Product Portfolio
    • 18.3.15.4. Business Strategies
    • 18.3.15.5. Recent Developments